$9.46
-2.2%eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
Chief Commercial Officer
Co-Founder & Vice President of Development
Compensation
$242,800
Co-Founder & Vice President of Research
Compensation
$245,670
Executive Vice President of Energy Transition
Founder & Independent Director
President & Chief Executive Officer
Compensation
$271,250
Vice President & Head of Business Development
Vice President of Communications
Vice President of Finance
Compensation
$183,750
During the last 12 months, insiders have purchased $3.05M and sold $15K worth of EXOZ shares, resulting in $3.04M of net buying activity.
0
0.00
1.5K
15.42K
-15K
-$15K
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
246.3K
3.05M
0
0.00
+3.1M
+$3.05M
Heltzen Michael
Officer: Chief Executive Officer
$2.93M
Nawaz Fouad
Officer: Vice President, Finance
$44K
Korman Tyler Paz
Officer: Vice President, Research
$37K
Opgenorth Paul Hideo
Officer: Vice President, Development
$37K
Korman Tyler Paz
Officer: Chief Scientific Officer
$15K
Strong bullish signal with $3.04M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
4 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
EXOZ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | June 20, 2025 | July 25, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.